Christoph E Hagemeyer
Overview
Explore the profile of Christoph E Hagemeyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Russell P, Esser L, Hagemeyer C, Voelcker N
Nat Nanotechnol
. 2022 Dec;
18(1):11-22.
PMID: 36536042
Extensive reports of pulmonary embolisms, ischaemic stroke and myocardial infarctions caused by coronavirus disease 2019 (COVID-19), as well as a significantly increased long-term risk of cardiovascular diseases in COVID-19 survivors,...
12.
Hashad R, Jap E, Casey J, Ho Y, Wright A, Thalmann C, et al.
Chemistry
. 2022 Dec;
29(11):e202202491.
PMID: 36451579
A highly effective 2-step system for site-specific antibody modification and conjugation of the monoclonal antibody Herceptin (commercially available under Trastuzumab) in a cysteine-independent manner was used to generate labelled antibodies...
13.
Hashad R, Singla R, Bhangu S, Jap E, Zhu H, Peleg A, et al.
Ultrason Sonochem
. 2022 Oct;
90:106183.
PMID: 36201933
Nisin, a peptide used as a natural food preservative, is employed in this work for the development of a novel nanocarrier system. Stable and uniform nisin-shelled nanoemulsions (NSNE) with a...
14.
Yu H, Palazzolo J, Ju Y, Niego B, Pan S, Hagemeyer C, et al.
Adv Healthc Mater
. 2022 Aug;
11(21):e2201151.
PMID: 36037807
The safe administration of thrombolytic agents is a challenge for the treatment of acute thrombosis. Lipid-based nanoparticle drug delivery technologies present opportunities to overcome the existing clinical limitations and deliver...
15.
Palazzolo J, Medcalf R, Hagemeyer C, Niego B
Res Pract Thromb Haemost
. 2022 Jul;
6(5).
PMID: 35873220
Background: The fibrinolytic system plays a critical role in maintaining hemostasis. Central to fibrinolysis is the degradation of fibrin by plasmin, produced in the circulation following the activation of plasminogen...
16.
Ardipradja K, Wichmann C, Hickson K, Rigopoulos A, Alt K, Pearce H, et al.
Int J Mol Sci
. 2022 Jul;
23(13).
PMID: 35805892
Positron emission tomography is the imaging modality of choice when it comes to the high sensitivity detection of key markers of thrombosis and inflammation, such as activated platelets. We, previously,...
17.
Palazzolo J, Ale A, Ho H, Jagdale S, Broughton B, Medcalf R, et al.
Blood Adv
. 2022 Apr;
7(4):561-574.
PMID: 35482909
Thrombolysis with tissue-type plasminogen activator (tPA) remains the main treatment for acute ischemic stroke. Nevertheless, tPA intervention is limited by a short therapeutic window, low recanalization rates, and a risk...
18.
Ezeani M, Noor A, Donnelly P, Niego B, Hagemeyer C
Sci Rep
. 2022 Apr;
12(1):5702.
PMID: 35383230
The identification of the fibrotic arrhythmogenic substrate as a means of improving the diagnosis and prediction of atrial fibrillation has been a focus of research for many years. The relationship...
19.
Yu H, Palazzolo J, Zhou J, Hu Y, Niego B, Pan S, et al.
ACS Appl Mater Interfaces
. 2022 Jan;
14(3):3740-3751.
PMID: 35019268
Thrombolytic (clot-busting) therapies with plasminogen activators (PAs) are first-line treatments against acute thrombosis and ischemic stroke. However, limitations such as narrow therapeutic windows, low success rates, and bleeding complications hinder...
20.